Correction: Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS-mutant Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
   Article
2. Histone Signatures Predict Therapeutic Efficacy in Breast Cancer.IEEE open journal of engineering in medicine and biology · 2020
   Article
3. A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.Scientific reports · 2017
   Article

Corrections and comments

• Erratum for
  Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.2015 · Xue, Yuahua [corrected to Xue, Yuhua]

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as